Pfizer Inc. (NYSE:PFE) Shares Sold by Duncker Streett & Co. Inc.

Duncker Streett & Co. Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 26.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,201 shares of the biopharmaceutical company’s stock after selling 10,159 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Pfizer were worth $748,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $26,000. Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the 4th quarter worth $31,000. Sierra Ocean LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer in the 3rd quarter worth $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.43 on Friday. The business has a 50-day moving average of $26.35 and a 200 day moving average of $27.33. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $149.78 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the business posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.